Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study. …
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
March 25, 2024 Australian Biotech
Latest Video
New Stories
-
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News -
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech